Artelo Biosciences Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Artelo Biosciences de winst en omzet met respectievelijk 10.2% en 94% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 53.9% per jaar.

Belangrijke informatie

10.2%

Groei van de winst

53.9%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.9%
Inkomstengroei	94.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	26 Nov 2024

Recente toekomstige groei-updates

Recent updates

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Aug 16

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Mar 28

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

May 20

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Feb 04

INO, VXRT, BTU and TTM among premarket gainers

Feb 02

Artelo Biosciences EPS misses by $0.04

Jan 14

Artelo Biosciences on go with cancer appetite recovery study

Nov 16

Winst- en omzetgroeiprognoses

NasdaqCM:ARTL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-19	-18	-18	2
12/31/2025	N/A	-11	-10	-10	3
12/31/2024	N/A	-8	-17	-17	3
9/30/2024	N/A	-9	-8	-8	N/A
6/30/2024	N/A	-10	-9	-9	N/A
3/31/2024	N/A	-10	-9	-9	N/A
12/31/2023	N/A	-9	-8	-8	N/A
9/30/2023	N/A	-10	-8	-8	N/A
6/30/2023	N/A	-9	-8	-8	N/A
3/31/2023	N/A	-10	-8	-8	N/A
12/31/2022	N/A	-10	-8	-8	N/A
9/30/2022	N/A	-13	-9	-9	N/A
6/30/2022	N/A	-13	-9	-9	N/A
3/31/2022	N/A	-12	-8	-8	N/A
12/31/2021	N/A	-12	-8	-8	N/A
11/30/2021	N/A	-9	-7	-7	N/A
8/31/2021	N/A	-7	-6	-6	N/A
5/31/2021	N/A	-7	-5	-5	N/A
2/28/2021	N/A	-5	-5	-5	N/A
11/30/2020	N/A	-5	-5	-5	N/A
8/31/2020	N/A	-5	-4	-4	N/A
5/31/2020	N/A	-4	-6	-5	N/A
2/29/2020	N/A	-4	-6	-4	N/A
11/30/2019	N/A	-3	-5	-3	N/A
8/31/2019	N/A	-2	-4	-3	N/A
5/31/2019	N/A	-2	-2	-2	N/A
2/28/2019	N/A	-2	-2	-2	N/A
11/30/2018	N/A	-3	-2	-2	N/A
8/31/2018	N/A	-2	N/A	-2	N/A
5/31/2018	N/A	-2	N/A	-1	N/A
2/28/2018	N/A	-1	N/A	-1	N/A
11/30/2017	N/A	-1	N/A	0	N/A
8/31/2017	N/A	0	N/A	0	N/A
5/31/2017	N/A	0	N/A	0	N/A
2/28/2017	N/A	0	N/A	0	N/A
11/30/2016	N/A	0	N/A	0	N/A
8/31/2016	N/A	0	N/A	0	N/A
5/31/2016	N/A	0	N/A	0	N/A
2/29/2016	N/A	0	N/A	0	N/A
11/30/2015	N/A	0	N/A	0	N/A
8/31/2015	N/A	0	N/A	0	N/A
5/31/2015	N/A	0	N/A	0	N/A
2/28/2015	N/A	0	N/A	0	N/A
11/30/2014	N/A	0	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ARTL de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ARTL de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ARTL de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat ARTL volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat ARTL volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ARTL naar verwachting over 3 jaar hoog zal zijn

Artelo Biosciences Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 16% to US$35.00

Price target increased to US$57.50

Price target decreased to US$4.08

Recent updates

New minor risk - Share price stability

Artelo Biosciences, Inc., Annual General Meeting, Dec 20, 2024

Artelo Biosciences, Inc. Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program

Insufficient new directors

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12

Artelo Biosciences, Inc. Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences, Inc. Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform

New major risk - Revenue and earnings growth

New major risk - Financial position

Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

New major risk - Revenue and earnings growth

Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11

Artelo Biosciences, Inc., Annual General Meeting, Jun 30, 2023

Price target decreased by 16% to US$35.00

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Price target increased to US$57.50

Artelo Biosciences, Inc. Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13

Artelo Biosciences, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$4.08

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results for Lead Program in Cancer-Related Cachexia

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Artelo Biosciences, Inc. Anticipates Accelerated Clinical Development for ART27.13

High number of new directors

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

Independent Director John Beck has left the company

Relief For Cancer Patients In Artelo Bioscience Pipeline

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences, Inc. Appoints Tamara A. Seymour to its Board of Directors

Artelo Biosciences, Inc. Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

New 90-day high: US$1.28

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia

INO, VXRT, BTU and TTM among premarket gainers

Artelo Biosciences EPS misses by $0.04

New 90-day high: US$1.00

Artelo Biosciences, Inc. Appoints Gregory R. Reyes to the Company’s Board of Directors

Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences on go with cancer appetite recovery study

New 90-day low: US$0.65

Artelo Biosciences, Inc. has completed a Composite Units Offering in the amount of $6.6 million.

Artelo Biosciences, Inc. Receives Ethics Approval to Commence Its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia

New 90-day low: US$0.71

New 90-day low - US$0.94

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven